Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis

Bhathena, Jasmine; Tomaro-Duchesneau, Catherine

doi:10.4172/2155-6156.s2-009

Cited by 8 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the potential of FA, due to its low solubility and permeability, FA absorption from the gastrointestinal tract (GIT) is limited when administered by conventional oral dosage forms, such as tablets and granules, hindering its efficacy [5]. Some micro and nanotechnological approaches have been done to improve the physicochemical, biopharmaceutical and pharmacokinetic of FA, thus increasing its bioavailability [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid

Lima

Khalil

Tominaga

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

This paper describes the development and in vitro evaluation of poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with chitosan (CS) for oral delivery of ferulic acid (FA). Nanoparticles were obtained by an emulsion evaporation technique and characterized. Furthermore, we evaluated the scavenging activity over hypochlorous acid (HOCl), the cytotoxicity over tumour cells and the in vitro intestinal permeability. Nanoparticles were spherical with a mean diameter of 242 nm, positive zeta potential and 50% of encapsulation efficiency. The in vitro release in phosphate buffered saline (PBS) (pH 7.4) demonstrated a prolonged and biphasic profile diffusion-controlled. In simulated gastrointestinal fluids, about 15% of FA was released in gastric fluid and a negligible release was observed in the intestinal fluid. In the HOCl scavenging activity and cytotoxicity over B16-F10 and HeLa cells, FA-loaded nanoparticles presented the same efficacy of the free drug. Besides, in the antioxidant and cytotoxic assay, CS contributed to FA effects. In the intestinal permeability study, FA-loaded nanoparticles exhibited a permeation of 6% through the Caco-2 monolayer and 20% through the Caco-2/HT29-MTX/Raji B co-culture. CS-coated PLGA nanoparticles are promising carriers for oral delivery of FA.

show abstract

Section: Introductionmentioning

confidence: 99%

Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid

Lima

Khalil

Tominaga

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Recent studies reported that in mice fed with a normal diet, oral administration of Lactobacillus fermentum CRL1446, as a supplement or functional food, produced an increase in intestinal FE activity, enhancing the bioavailability of antioxidant FA, thus improving oxidative status [ 8 , 14 ]. Moreover, it has been reported that the administration of lactic acid bacteria (LAB) with FE activity can enhance metabolic activity markers in animal models of metabolic syndrome and diabetes [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Lactobacillus fermentum CRL1446 Ameliorates Oxidative and Metabolic Parameters by Increasing Intestinal Feruloyl Esterase Activity and Modulating Microbiota in Caloric-Restricted Mice

et al. 2016

View full text Add to dashboard Cite

The purpose of this study was to determine whether the administration of the feruloyl esterase (FE)-producing strain Lactobacillus fermentum CRL1446 enhances metabolic and oxidative parameters in caloric-restricted (CR) mice. Balb/c male mice were divided into ad libitum fed Group (ALF Group), CR diet Group (CR Group) and CR diet plus L. fermentum Group (CR-Lf Group). CR diet was administered during 45 days and CRL1446 strain was given in the dose of 108 cells/mL/day/mouse. FE activity was determined in intestinal mucosa and content at Day 1, 20 and 45. Triglyceride, total cholesterol, glucose, thiobarbituric acid reactive substances (TBARS) levels and glutathione reductase activity were determined in plasma. Gut microbiota was evaluated by high-throughput sequencing of 16S rRNA gene amplicons. At Day 45, total intestinal FE activity in CR-Lf Group was higher (p = 0.020) than in CR and ALF groups and an improvement in both metabolic (reductions in triglyceride (p = 0.0025), total cholesterol (p = 0.005) and glucose (p < 0.0001) levels) and oxidative (decrease of TBARS levels and increase of plasmatic glutathione reductase activity (p = 0.006)) parameters was observed, compared to ALF Group. CR diet increased abundance of Bacteroidetes and CRL1446 administration increased abundance of Bifidobacterium and Lactobacillus genus. L. fermentun CRL1446 exerted a bifidogenic effect under CR conditions.

show abstract

“…The presence of a higher probiotic viability and FAE activity resulted in significant reductions in serum total cholesterol, LDL cholesterol and serum triglyceride levels in diet-induced hypercholesterolemic hamsters [ 11 ]. Similar studies were also performed with microencapsulated L. fermentum for the treatment and prevention of metabolic syndrome [ 15 ].…”

Section: Microencapsulated Microorganismsmentioning

confidence: 90%

Microencapsulation for the Therapeutic Delivery of Drugs, Live Mammalian and Bacterial Cells, and Other Biopharmaceutics: Current Status and Future Directions

Tomaro-Duchesneau

Saha

Malhotra

et al. 2013

Journal of Pharmaceutics

View full text Add to dashboard Cite

Microencapsulation is a technology that has shown significant promise in biotherapeutics, and other applications. It has been proven useful in the immobilization of drugs, live mammalian and bacterial cells and other cells, and other biopharmaceutics molecules, as it can provide material structuration, protection of the enclosed product, and controlled release of the encapsulated contents, all of which can ensure efficient and safe therapeutic effects. This paper is a comprehensive review of microencapsulation and its latest developments in the field. It provides a comprehensive overview of the technology and primary goals of microencapsulation and discusses various processes and techniques involved in microencapsulation including physical, chemical, physicochemical, and other methods involved. It also summarizes the state-of-the-art successes of microencapsulation, specifically with regard to the encapsulation of microorganisms, mammalian cells, drugs, and other biopharmaceutics in various diseases. The limitations and future directions of microencapsulation technologies are also discussed.

show abstract

Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis

Cited by 8 publications

References 29 publications

Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid

Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid

Lactobacillus fermentum CRL1446 Ameliorates Oxidative and Metabolic Parameters by Increasing Intestinal Feruloyl Esterase Activity and Modulating Microbiota in Caloric-Restricted Mice

Microencapsulation for the Therapeutic Delivery of Drugs, Live Mammalian and Bacterial Cells, and Other Biopharmaceutics: Current Status and Future Directions

Contact Info

Product

Resources

About